Thrivent Financial for Lutherans Sells 534 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Thrivent Financial for Lutherans cut its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,689 shares of the company’s stock after selling 534 shares during the period. Thrivent Financial for Lutherans owned approximately 0.08% of Pacira BioSciences worth $672,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Wealthfront Advisers LLC acquired a new position in shares of Pacira BioSciences in the 4th quarter worth approximately $1,001,000. AlphaQuest LLC grew its position in Pacira BioSciences by 43.4% in the fourth quarter. AlphaQuest LLC now owns 13,493 shares of the company’s stock valued at $254,000 after acquiring an additional 4,083 shares during the period. Amundi raised its stake in Pacira BioSciences by 200.8% during the fourth quarter. Amundi now owns 23,114 shares of the company’s stock worth $429,000 after acquiring an additional 15,431 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares during the period. Finally, Banco Santander S.A. boosted its stake in shares of Pacira BioSciences by 5.8% in the 4th quarter. Banco Santander S.A. now owns 126,900 shares of the company’s stock valued at $2,391,000 after purchasing an additional 6,900 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Stock Up 3.4 %

Shares of PCRX opened at $24.89 on Thursday. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.26 and a beta of 0.70. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business’s fifty day moving average price is $24.89 and its two-hundred day moving average price is $20.20.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PCRX shares. HC Wainwright increased their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays lifted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences presently has a consensus rating of “Hold” and an average target price of $27.22.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.